Cargando…

Second-line treatment in renal cell carcinoma: clinical experience and decision making

Currently, conventional treatments for metastatic RCC (mRCC) include immune-based combination regimens and/or targeted therapies, the latter mainly acting on angiogenesis, a key element of the process of tumor growth and spread. Although these agents proved able to improve patients’ outcomes, drug r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guadalupi, Valentina, Cartenì, Giacomo, Iacovelli, Roberto, Porta, Camillo, Pappagallo, Giovanni, Ricotta, Riccardo, Procopio, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216352/ https://www.ncbi.nlm.nih.gov/pubmed/34211586 http://dx.doi.org/10.1177/17562872211022870

Ejemplares similares

First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series
por: Buti, Sebastiano, et al.
Publicado: (2021)

Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?
por: Pantano, Francesco, et al.
Publicado: (2015)

Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy
por: Bottiglieri, Achille, et al.
Publicado: (2022)

Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma
por: Sepe, Pierangela, et al.
Publicado: (2021)

Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
por: Raimondi, Alessandra, et al.
Publicado: (2020)

Targeted treatments in advanced renal cell carcinoma: focus on axitinib
por: Verzoni, Elena, et al.
Publicado: (2014)

Nucleotide second messengers in bacterial decision making
por: Thompson, Catriona MA, et al.
Publicado: (2020)

Qualitative study of patients’ decision-making when accepting second-line treatment after failure of first-line chemotherapy
por: Pujol, Jean-Louis, et al.
Publicado: (2018)

Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma
por: Santoni, Matteo, et al.
Publicado: (2013)

Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results
por: Facchini, Gaetano, et al.
Publicado: (2019)

First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts
por: Aeppli, S., et al.
Publicado: (2021)

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
por: Verzoni, Elena, et al.
Publicado: (2019)

Choosing the right cell line for renal cell cancer research
por: Brodaczewska, Klaudia K., et al.
Publicado: (2016)

Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma
por: Santini, Daniele, et al.
Publicado: (2016)

Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?
por: Mennitto, Alessia, et al.
Publicado: (2020)

Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey
por: Santini, Daniele, et al.
Publicado: (2013)

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
por: Santoni, Matteo, et al.
Publicado: (2019)

A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)
por: Procopio, Giuseppe, et al.
Publicado: (2022)

Clinical Decision Making in Renal Pain Management
por: Aganovic, Damir, et al.
Publicado: (2012)

Second-line treatment for renal cell cancer
por: Di Lorenzo, G, et al.
Publicado: (2012)

The second generation of accelerators for CERN, 1956-1965: the decision-making process
por: Pestre, Dominique
Publicado: (1987)

Quantifying pediatric patient need for second- and third-line HIV treatment: A tool for decision-making in resource-limited settings
por: Mohammed, Perry, et al.
Publicado: (2019)

Heart Rate Variability and Decision-Making: Autonomic Responses in Making Decisions
por: Forte, Giuseppe, et al.
Publicado: (2021)

Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?
por: Santoni, Matteo, et al.
Publicado: (2015)

Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract: A case report
por: Pirozzi, Angelo, et al.
Publicado: (2019)

Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies
por: Cosmai, Laura, et al.
Publicado: (2020)

Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies
por: Procopio, G, et al.
Publicado: (2012)

Giant Renal Artery Aneurysms: Decision-Making Dilemmas
por: Ramdass, Michael J.
Publicado: (2013)

Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach
por: Fiorentino, Michelangelo, et al.
Publicado: (2016)

Shared Decision Making for the Emergency Provider: Engaging Patients When Seconds Count
por: Kanzaria, Hemal K., et al.
Publicado: (2020)

Chemotherapy or Targeted Therapy as Second-Line Treatment of Advanced Gastric Cancer. A Systematic Review and Meta-Analysis of Published Studies
por: Iacovelli, Roberto, et al.
Publicado: (2014)

Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication
por: Buti, Sebastiano, et al.
Publicado: (2023)

Bright line or lottery? On significance and value in medical decision making
por: Mahlich, Jörg, et al.
Publicado: (2021)

Playing the Devil’s Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? – ie Strategies to Revert Resistance to mTOR Inhibitors
por: Pezzicoli, Gaetano, et al.
Publicado: (2021)

Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer
por: Riccardi, Ferdinando, et al.
Publicado: (2010)

How the brain prevents a second error in a perceptual decision-making task
por: Perri, Rinaldo Livio, et al.
Publicado: (2016)

The second patient? Family members of cancer patients and their role in end-of-life decision making
por: Laryionava, Katsiaryna, et al.
Publicado: (2018)

Sub-second Dopamine and Serotonin Signaling in Human Striatum during Perceptual Decision-Making
por: Bang, Dan, et al.
Publicado: (2020)

Artificial intelligence-based prediction of overall survival in metastatic renal cell carcinoma
por: Barkan, Ella, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pt80nbkr1cr9kffp32opp3nh61